Uchechukwu Bethel Abioke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Uchechukwu Bethel Abioke has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Chinyere Elohor Egbordi3 shared publications
- Obiageri Ihuarulam Okeoma
Department of Medical Laboratory Science, Faculty of Basic Medical And Applied Sciences, Trinity University, Yaba, Lagos, Nigeria
3 shared publications - Elona Erezi
Sydani Group
2 shared publications - Olabode Olubunmi Joy2 shared publications
- Reginald Oyortey2 shared publications
- Tosin Abiodun Aderanti
Department of Chemical and Environmental Sciences, Babcock University, Ilishan-Remo, Ogun State, Nigeria
2 shared publications
Latest Publications
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 152-164
Medical Nomenclature and Patient Understanding: Lessons from the Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome Transition
Background: Medical nomenclature can influence patients, clinicians, diagnostic accuracy, and health outcomes. On 12 May 2026, after a multi-year global consensus process, polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS). The change reflected the recognition that the older term was scientifically imprecise and could contribute to delayed diagnosis, fragmented care, stigma, and limited patient understanding. Objectives: Using the PCOS-to-PMOS transition as a case study, this narrative review examines how an imprecise name may contribute to diagnostic delay, stigma, clinician confusion, and poorer outcomes. It synthesises evidence across five linked questions: how disease names shape patient understanding and health literacy; how they contribute to diagnostic delay and misdiagnosis; how they relate to stigma and psychosocial burden; how they influence clinician decision-making and care coordination; and what these effects imply for healthcare quality and patient safety. Methods: A narrative review of peer-reviewed literature, professional society publications, and grey literature was conducted using PubMed, Scopus, Web of Science, Google Scholar, and professional society websites. Search terms related to the phenomenon of interest, including “disease nomenclature,” “disease naming,” and “medical terminology,” were combined with terms describing its proposed effects, including “patient understanding,” “health literacy,” “diagnostic delay,” “stigma,” and “medical cognition,” and with condition-specific terms, including “PCOS,” “polycystic ovary syndrome,” and “PMOS.” Priority was given to studies addressing the effects of disease names on diagnosis, clinical outcomes, and health literacy. Findings: The evidence indicates that an imprecise name can weaken diagnostic accuracy through identifiable cognitive pathways. Cognitive load theory, conceptual anchoring, and semantic priming together explain how a name shapes patients’ and clinicians’ understanding. Historical reforms, from “hysteria” to specific diagnoses and from “Mongolism” to Down syndrome, show that more accurate naming has accompanied improved recognition and care. PCOS affects approximately one in eight women, or more than 170 million worldwide, yet up to 70% may remain undiagnosed or face diagnostic delays of several years. The PMOS revision illustrates how evidence-based terminology can be aligned with current scientific understanding. Conclusions: Medical terminology is not merely semantic; it shapes clinical reasoning, patient comprehension, and diagnostic and therapeutic pathways, with potential consequences for outcomes. The PCOS-to-PMOS transition shows that systematic, evidence-based nomenclature change is feasible and that disease names should reflect scientific understanding while supporting optimal care. Healthcare systems should treat nomenclature accuracy as a component of quality improvement and patient safety.
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 152-164
Medical Nomenclature and Patient Understanding: Lessons from the Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome Transition
Background: Medical nomenclature can influence patients, clinicians, diagnostic accuracy, and health outcomes. On 12 May 2026, after a multi-year global consensus process, polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS). The change reflected the recognition that the older term was scientifically imprecise and could contribute to delayed diagnosis, fragmented care, stigma, and limited patient understanding. Objectives: Using the PCOS-to-PMOS transition as a case study, this narrative review examines how an imprecise name may contribute to diagnostic delay, stigma, clinician confusion, and poorer outcomes. It synthesises evidence across five linked questions: how disease names shape patient understanding and health literacy; how they contribute to diagnostic delay and misdiagnosis; how they relate to stigma and psychosocial burden; how they influence clinician decision-making and care coordination; and what these effects imply for healthcare quality and patient safety. Methods: A narrative review of peer-reviewed literature, professional society publications, and grey literature was conducted using PubMed, Scopus, Web of Science, Google Scholar, and professional society websites. Search terms related to the phenomenon of interest, including “disease nomenclature,” “disease naming,” and “medical terminology,” were combined with terms describing its proposed effects, including “patient understanding,” “health literacy,” “diagnostic delay,” “stigma,” and “medical cognition,” and with condition-specific terms, including “PCOS,” “polycystic ovary syndrome,” and “PMOS.” Priority was given to studies addressing the effects of disease names on diagnosis, clinical outcomes, and health literacy. Findings: The evidence indicates that an imprecise name can weaken diagnostic accuracy through identifiable cognitive pathways. Cognitive load theory, conceptual anchoring, and semantic priming together explain how a name shapes patients’ and clinicians’ understanding. Historical reforms, from “hysteria” to specific diagnoses and from “Mongolism” to Down syndrome, show that more accurate naming has accompanied improved recognition and care. PCOS affects approximately one in eight women, or more than 170 million worldwide, yet up to 70% may remain undiagnosed or face diagnostic delays of several years. The PMOS revision illustrates how evidence-based terminology can be aligned with current scientific understanding. Conclusions: Medical terminology is not merely semantic; it shapes clinical reasoning, patient comprehension, and diagnostic and therapeutic pathways, with potential consequences for outcomes. The PCOS-to-PMOS transition shows that systematic, evidence-based nomenclature change is feasible and that disease names should reflect scientific understanding while supporting optimal care. Healthcare systems should treat nomenclature accuracy as a component of quality improvement and patient safety.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 1-19
Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review
Background: Type 2 diabetes mellitus is a chronic metabolic condition affecting millions of adults worldwide. Despite newer treatment modalities such as GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide, insulin remains vital for many patients. This is particularly the case for those with advanced beta-cell dysfunction, severe hyperglycaemia, or inadequate glycaemic control despite non-insulin therapies. Objective: This narrative review outlines the changing landscape of insulin therapy for type 2 diabetes, and focuses on personalisation of treatment, combination therapy, minimising adverse events, digital technologies and safe de-intensification. Methods: Literature was reviewed from PubMed, Scopus, and Google Scholar, focusing mainly on clinical trials, systematic reviews, meta-analyses, major guidelines, and relevant expert reviews published between 2016 and 2026. Landmark older studies were included where clinically relevant. Key Findings: The use of insulin is still strongly influencing glycaemic control but is now more guided by new therapies and technologies. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide can be combined to lower the amount of insulin needed for treatment, help prevent weight gain, improve cardiometabolic outcomes, and decrease treatment burden in certain patients. New technologies such as smart insulin pens and digital titration devices facilitate more accurate insulin dosing and decrease the risk of hypoglycaemia. Patient-led titration and safe de-intensification are also important particularly for high-risk individuals for hypoglycaemia. Conclusion: Insulin therapy remains indispensable in type 2 diabetes care, but its optimal use now requires a more digitally supported, and patient-centred approach. The key concern is no longer whether insulin remains necessary, but how its use can be optimised to improve effectiveness and fit safely within modern type 2 diabetes care.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 1-19
Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review
Background: Type 2 diabetes mellitus is a chronic metabolic condition affecting millions of adults worldwide. Despite newer treatment modalities such as GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide, insulin remains vital for many patients. This is particularly the case for those with advanced beta-cell dysfunction, severe hyperglycaemia, or inadequate glycaemic control despite non-insulin therapies. Objective: This narrative review outlines the changing landscape of insulin therapy for type 2 diabetes, and focuses on personalisation of treatment, combination therapy, minimising adverse events, digital technologies and safe de-intensification. Methods: Literature was reviewed from PubMed, Scopus, and Google Scholar, focusing mainly on clinical trials, systematic reviews, meta-analyses, major guidelines, and relevant expert reviews published between 2016 and 2026. Landmark older studies were included where clinically relevant. Key Findings: The use of insulin is still strongly influencing glycaemic control but is now more guided by new therapies and technologies. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide can be combined to lower the amount of insulin needed for treatment, help prevent weight gain, improve cardiometabolic outcomes, and decrease treatment burden in certain patients. New technologies such as smart insulin pens and digital titration devices facilitate more accurate insulin dosing and decrease the risk of hypoglycaemia. Patient-led titration and safe de-intensification are also important particularly for high-risk individuals for hypoglycaemia. Conclusion: Insulin therapy remains indispensable in type 2 diabetes care, but its optimal use now requires a more digitally supported, and patient-centred approach. The key concern is no longer whether insulin remains necessary, but how its use can be optimised to improve effectiveness and fit safely within modern type 2 diabetes care.
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 1-24
Energy Poverty and Gendered Inequities in African Communities: A Review of Health Impacts and Policy Gaps
Energy poverty remains one of the most widespread structural barriers to human development across sub-Saharan and North Africa. Its impact is not experienced equally across society, but rather disproportionately borne by women and girls, influenced by deeply rooted gender inequalities and societal division of energy-related domestic tasks into women's domain in most African societies. This review focuses on the African continent and draws on peer-reviewed studies, multilateral agency reports, and policy documents, primarily from 2015 to 2026. The aim is to critically review, from a gender perspective, the nature of energy poverty in Africa. Specific aims are to: (1) describe the burden and distribution of energy poverty by region in Africa; (2) capture health outcomes of gendered exposure to energy; (3) explore structural and governance drivers of the gender-energy nexus; (4) critically question policy actions and highlight persistent gaps in design and (5) identify gaps in evidence base. A narrative review design was used. The literature was collected from four databases (PubMed, Scopus, Web of Science, and Google Scholar), as well as grey literature from the WHO, IEA, World Bank, and the Clean Cooking Alliance. The main publication period was 2015-2026, and studies conducted prior to that were retained only if their conclusions had not been replicated. Sources that specifically mention Africa were included. Sources that were not peer-reviewed, opinion pieces without empirical support, and studies relevant only to contexts outside Africa were excluded. Women living in energy-poor households are exposed to long-term indoor air pollution from burning biomass fuels such as firewood, charcoal, or crop residues. This exposure increases their risk of respiratory illness, cardiovascular disease, and other long-term health problems. Gender-sensitivity in policy responses has been lacking, focusing on how to disseminate technology rather than the social and economic factors that affect women's access to and ability to sustain clean energy transitions. In conclusion, energy poverty as a gender justice problem needs policy frameworks that recognize women as producers, not consumers. Integrating gender-responsive design into electrification and clean cooking programmes, and closing persistent gaps in sex-disaggregated data, are prerequisites for meaningful progress.
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 1-24
Energy Poverty and Gendered Inequities in African Communities: A Review of Health Impacts and Policy Gaps
Energy poverty remains one of the most widespread structural barriers to human development across sub-Saharan and North Africa. Its impact is not experienced equally across society, but rather disproportionately borne by women and girls, influenced by deeply rooted gender inequalities and societal division of energy-related domestic tasks into women's domain in most African societies. This review focuses on the African continent and draws on peer-reviewed studies, multilateral agency reports, and policy documents, primarily from 2015 to 2026. The aim is to critically review, from a gender perspective, the nature of energy poverty in Africa. Specific aims are to: (1) describe the burden and distribution of energy poverty by region in Africa; (2) capture health outcomes of gendered exposure to energy; (3) explore structural and governance drivers of the gender-energy nexus; (4) critically question policy actions and highlight persistent gaps in design and (5) identify gaps in evidence base. A narrative review design was used. The literature was collected from four databases (PubMed, Scopus, Web of Science, and Google Scholar), as well as grey literature from the WHO, IEA, World Bank, and the Clean Cooking Alliance. The main publication period was 2015-2026, and studies conducted prior to that were retained only if their conclusions had not been replicated. Sources that specifically mention Africa were included. Sources that were not peer-reviewed, opinion pieces without empirical support, and studies relevant only to contexts outside Africa were excluded. Women living in energy-poor households are exposed to long-term indoor air pollution from burning biomass fuels such as firewood, charcoal, or crop residues. This exposure increases their risk of respiratory illness, cardiovascular disease, and other long-term health problems. Gender-sensitivity in policy responses has been lacking, focusing on how to disseminate technology rather than the social and economic factors that affect women's access to and ability to sustain clean energy transitions. In conclusion, energy poverty as a gender justice problem needs policy frameworks that recognize women as producers, not consumers. Integrating gender-responsive design into electrification and clean cooking programmes, and closing persistent gaps in sex-disaggregated data, are prerequisites for meaningful progress.
- 24 April 2026
- Published by Sciencedomain International in Journal of Engineering Research and Reports
- Vol. 28 (5) , 115-131
Thermal Performance, Efficiency and Applications of Solar-driven Cooling Systems in Hot Climate Areas: A Narrative Review
The Global Cooling Watch predicts that the cooling demand will triple by the year 2050. With heatwaves being the deadliest climate hazard, the burden of cooling is increasing, especially in the densely populated areas of equatorial cities. Interestingly, the sun, which promotes the cooling demand, is itself the solution to excessive heat. This thermodynamic alignment is unique because there is no other thermodynamic system that utilizes solar energy so accurately to satisfy demand. In spite of all these benefits, solar cooling systems represent fewer than 1,500 large-scale installations across the world. To tackle this, we located relevant literature by searching in Scopus, Web of Science, and Google Scholar, and further articles were located using citation chains. Our target markets are hot climatic areas such as the Middle East and North Africa, South and Southeast Asia, Sub-Saharan Africa, and some areas in Mediterranean Europe. We used a single solar-to-cooling coefficient of performance (COPsol) to enable us to compare them with other technologies. In the studies considered, we discover that across all technologies, measured performance is consistently lower than manufacturer-rated values, with reported gaps ranging from approximately 6% to 21% under peak summer conditions. Ambient temperature, heat rejection limits and system operation play a powerful role on performance as opposed to design specifications. These results emphasize the constraints of using rated values of performance on systems design in hot climates. Future implementation must focus on data field-tested and enhance heat rejection plans as well as standard performance measures to ensure steady system sizing and functionality.
- 24 April 2026
- Published by Sciencedomain International in Journal of Engineering Research and Reports
- Vol. 28 (5) , 115-131
Thermal Performance, Efficiency and Applications of Solar-driven Cooling Systems in Hot Climate Areas: A Narrative Review
The Global Cooling Watch predicts that the cooling demand will triple by the year 2050. With heatwaves being the deadliest climate hazard, the burden of cooling is increasing, especially in the densely populated areas of equatorial cities. Interestingly, the sun, which promotes the cooling demand, is itself the solution to excessive heat. This thermodynamic alignment is unique because there is no other thermodynamic system that utilizes solar energy so accurately to satisfy demand. In spite of all these benefits, solar cooling systems represent fewer than 1,500 large-scale installations across the world. To tackle this, we located relevant literature by searching in Scopus, Web of Science, and Google Scholar, and further articles were located using citation chains. Our target markets are hot climatic areas such as the Middle East and North Africa, South and Southeast Asia, Sub-Saharan Africa, and some areas in Mediterranean Europe. We used a single solar-to-cooling coefficient of performance (COPsol) to enable us to compare them with other technologies. In the studies considered, we discover that across all technologies, measured performance is consistently lower than manufacturer-rated values, with reported gaps ranging from approximately 6% to 21% under peak summer conditions. Ambient temperature, heat rejection limits and system operation play a powerful role on performance as opposed to design specifications. These results emphasize the constraints of using rated values of performance on systems design in hot climates. Future implementation must focus on data field-tested and enhance heat rejection plans as well as standard performance measures to ensure steady system sizing and functionality.
- 9 April 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (3) , ehdi035
Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
Obesity is a chronic condition driven in part by disrupted appetite control and changes in gastrointestinal function, both of which contribute to excessive energy intake and progressive weight gain. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to produce meaningful weight loss in non-diabetic adults. Despite its growing clinical use, the physiological processes through which semaglutide influences appetite and gastric emptying have not been clearly brought together. This systematic review explored how semaglutide affects appetite regulation and gastric emptying, and how these effects relate to weight reduction. A systematic search was conducted in PubMed, Google Scholar, and Dimensions for studies published between 2021 and 2026, in line with PRISMA 2020 guidelines. Study screening, data extraction, and risk-of-bias assessment were carried out using Covidence by two independent reviewers, with a third reviewer resolving any disagreements. Four studies met the inclusion criteria, consisting of randomized controlled trials and one retrospective cohort study. Across randomized trials, semaglutide was consistently associated with greater improvements in appetite-related outcomes compared with placebo, including reductions in hunger scores and overall energy intake. Studies that assessed gastric physiology reported a notable delay in gastric emptying with semaglutide, particularly during the early stages of treatment. These physiological changes occurred alongside greater weight loss in semaglutide-treated participants compared with control groups. Longer-term findings suggested that appetite suppression was maintained over time and accompanied by clinically meaningful weight reduction, while observational data supported the effectiveness of semaglutide in routine clinical practice. Overall, the findings suggest that the weight-reducing effects of semaglutide in non-diabetic adults with obesity are closely tied to its ability to suppress appetite and slow gastric emptying. These mechanisms appear to play a central role in its therapeutic benefits and help explain the sustained weight loss observed with treatment.
- 9 April 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (3) , ehdi035
Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
Obesity is a chronic condition driven in part by disrupted appetite control and changes in gastrointestinal function, both of which contribute to excessive energy intake and progressive weight gain. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to produce meaningful weight loss in non-diabetic adults. Despite its growing clinical use, the physiological processes through which semaglutide influences appetite and gastric emptying have not been clearly brought together. This systematic review explored how semaglutide affects appetite regulation and gastric emptying, and how these effects relate to weight reduction. A systematic search was conducted in PubMed, Google Scholar, and Dimensions for studies published between 2021 and 2026, in line with PRISMA 2020 guidelines. Study screening, data extraction, and risk-of-bias assessment were carried out using Covidence by two independent reviewers, with a third reviewer resolving any disagreements. Four studies met the inclusion criteria, consisting of randomized controlled trials and one retrospective cohort study. Across randomized trials, semaglutide was consistently associated with greater improvements in appetite-related outcomes compared with placebo, including reductions in hunger scores and overall energy intake. Studies that assessed gastric physiology reported a notable delay in gastric emptying with semaglutide, particularly during the early stages of treatment. These physiological changes occurred alongside greater weight loss in semaglutide-treated participants compared with control groups. Longer-term findings suggested that appetite suppression was maintained over time and accompanied by clinically meaningful weight reduction, while observational data supported the effectiveness of semaglutide in routine clinical practice. Overall, the findings suggest that the weight-reducing effects of semaglutide in non-diabetic adults with obesity are closely tied to its ability to suppress appetite and slow gastric emptying. These mechanisms appear to play a central role in its therapeutic benefits and help explain the sustained weight loss observed with treatment.
- 24 March 2026
- Published by IK Press in Journal of Global Ecology and Environment
- Vol. 22 (2) , 203-218
Environmental Implications of Plastic-degrading Bacterial Enzymes in Polyethylene Terephthalate Bioremediation
Polyethylene terephthalate (PET) is one of the most persistent synthetic polymers found in terrestrial and aquatic environments, and is responsible for long-term plastic accumulation and the formation of microplastic. Traditional mechanical and chemical recycling methods are still limited by contamination, degradation of polymer quality, energy consumption, and only suitable for concentrated waste streams. This review discusses and summarizes the available peer-reviewed data regarding the bacterial enzymes that degrade polyethylene terephthalate (PETase, MHETase, cutinases, and engineered variants of hydrolases). The literature was searched for the polyethyleneterephthalate biodegradation, bacterial enzymes, PETase, MHETase, plastisphere microorganisms, enzymatic recycling, environmental risk and bioremediation using major scientific databases such as PubMed, Scopus, Web of Science, ScienceDirect and Google Scholar. Only studies that focused on bacterial sources and isolation, enzymatic mechanisms, protein engineering, environmental effects, or scalability of polyethylene terephthalate degradation were included. Overall, there were 34 articles included in the final synthesis. The results indicate that bacterial enzymes can depolymerise PET to recoverable intermediates and monomers, although the practical use of these enzymes requires consideration of the crystallinity of the substrate, their catalytic efficiency under ambient conditions, enzyme instability and lack of knowledge of intermediates involved in natural ecosystems. There is current evidence that contained industrial enzymatic recycling is the most advanced near-term application, whereas open-environment bioremediation needs a more robust ecological risk assessment, standardised tests, and regulation. The production of environmentally robust enzyme variants, microbial consortia, life-cycle assessment, and safety frameworks for responsible deployment are promising areas for future research.
- 24 March 2026
- Published by IK Press in Journal of Global Ecology and Environment
- Vol. 22 (2) , 203-218
Environmental Implications of Plastic-degrading Bacterial Enzymes in Polyethylene Terephthalate Bioremediation
Polyethylene terephthalate (PET) is one of the most persistent synthetic polymers found in terrestrial and aquatic environments, and is responsible for long-term plastic accumulation and the formation of microplastic. Traditional mechanical and chemical recycling methods are still limited by contamination, degradation of polymer quality, energy consumption, and only suitable for concentrated waste streams. This review discusses and summarizes the available peer-reviewed data regarding the bacterial enzymes that degrade polyethylene terephthalate (PETase, MHETase, cutinases, and engineered variants of hydrolases). The literature was searched for the polyethyleneterephthalate biodegradation, bacterial enzymes, PETase, MHETase, plastisphere microorganisms, enzymatic recycling, environmental risk and bioremediation using major scientific databases such as PubMed, Scopus, Web of Science, ScienceDirect and Google Scholar. Only studies that focused on bacterial sources and isolation, enzymatic mechanisms, protein engineering, environmental effects, or scalability of polyethylene terephthalate degradation were included. Overall, there were 34 articles included in the final synthesis. The results indicate that bacterial enzymes can depolymerise PET to recoverable intermediates and monomers, although the practical use of these enzymes requires consideration of the crystallinity of the substrate, their catalytic efficiency under ambient conditions, enzyme instability and lack of knowledge of intermediates involved in natural ecosystems. There is current evidence that contained industrial enzymatic recycling is the most advanced near-term application, whereas open-environment bioremediation needs a more robust ecological risk assessment, standardised tests, and regulation. The production of environmentally robust enzyme variants, microbial consortia, life-cycle assessment, and safety frameworks for responsible deployment are promising areas for future research.
- 24 March 2026
- Published by IK Press in Journal of Global Ecology and Environment
- Vol. 22 (2) , 91-108
A Narrative Review of the Environmental and Public Health Implications of Carbon Sequestration in the Amazon Rainforest
The Amazon Rainforest stores an estimated 150–200 petagrams of carbon in its biomass and soils, making it the largest terrestrial carbon reservoir on Earth. This narrative review assesses the Amazon’s role in regulating global and regional climate, examines emerging evidence on the weakening of its carbon sink function, and evaluates the environmental and public health consequences of ongoing forest degradation. Drawing on research from 2015 to 2025, we analyze carbon sequestration processes, hydrological functions, including the “flying rivers” system, and feedback mechanisms driving parts of the southeastern Amazon toward a shift from carbon sink to carbon source. We also consider methodological differences in biomass estimation, particularly across remote sensing approaches, and their implications for carbon accounting. In addition, we highlight the health impacts of deforestation, including respiratory illness from wildfire smoke, heat-related illness, the spread of vector-borne diseases such as malaria and dengue, and risks to food and water security. We also assess current policy frameworks, including the Paris Agreement, REDD+, and national conservation laws. Overall, we argue that the Amazon is essential to planetary health, and that protecting it will require stronger and more effective governance, not just incremental changes to existing policies.
- 24 March 2026
- Published by IK Press in Journal of Global Ecology and Environment
- Vol. 22 (2) , 91-108
A Narrative Review of the Environmental and Public Health Implications of Carbon Sequestration in the Amazon Rainforest
The Amazon Rainforest stores an estimated 150–200 petagrams of carbon in its biomass and soils, making it the largest terrestrial carbon reservoir on Earth. This narrative review assesses the Amazon’s role in regulating global and regional climate, examines emerging evidence on the weakening of its carbon sink function, and evaluates the environmental and public health consequences of ongoing forest degradation. Drawing on research from 2015 to 2025, we analyze carbon sequestration processes, hydrological functions, including the “flying rivers” system, and feedback mechanisms driving parts of the southeastern Amazon toward a shift from carbon sink to carbon source. We also consider methodological differences in biomass estimation, particularly across remote sensing approaches, and their implications for carbon accounting. In addition, we highlight the health impacts of deforestation, including respiratory illness from wildfire smoke, heat-related illness, the spread of vector-borne diseases such as malaria and dengue, and risks to food and water security. We also assess current policy frameworks, including the Paris Agreement, REDD+, and national conservation laws. Overall, we argue that the Amazon is essential to planetary health, and that protecting it will require stronger and more effective governance, not just incremental changes to existing policies.
- 6 January 2026
- Published by Sciencedomain International in Journal of Cancer and Tumor International
- Vol. 16 (1) , 104-124
From Bench to Bedside: Structural and Biological Barriers to Therapeutic Translation in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, driven largely by KRAS mutations and profound therapeutic resistance. This review summarizes recent translational strategies aimed at bridging laboratory discoveries with clinical application, including precision oncology, rational combination therapies, and stromal modulation. We examine preclinical and clinical studies that highlight mechanistic insights such as KRAS inhibition, PARP-targeted therapy, and multi-drug regimens, drawing lessons from genetically engineered mouse models, patient-derived xenografts, and biomarker-guided clinical trials. Recent advances demonstrate that previously undruggable targets, including KRAS, can now be modulated using mutation-specific inhibitors and combination therapies, achieving complete tumor regression in preclinical models. PARP inhibitors in BRCA-mutated PDAC exemplify the translation of precision medicine into patient benefit. Adaptive, biomarker-driven trials enhance the detection of therapeutic signals, while stromal reprogramming improves drug delivery and immune accessibility. Artificial intelligence and systems biology further support predictive modeling and optimization of trial design. Overall, translational research in PDAC shows that persistent mechanistic exploration, combination strategies, and innovative trial designs can overcome historical therapeutic barriers. Despite systemic challenges such as funding, regulatory hurdles, and structural limitations, these approaches provide a roadmap for improving clinical outcomes. Continued interdisciplinary collaboration and precision-guided interventions will be essential to fully realize the potential of these discoveries.
- 6 January 2026
- Published by Sciencedomain International in Journal of Cancer and Tumor International
- Vol. 16 (1) , 104-124
From Bench to Bedside: Structural and Biological Barriers to Therapeutic Translation in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, driven largely by KRAS mutations and profound therapeutic resistance. This review summarizes recent translational strategies aimed at bridging laboratory discoveries with clinical application, including precision oncology, rational combination therapies, and stromal modulation. We examine preclinical and clinical studies that highlight mechanistic insights such as KRAS inhibition, PARP-targeted therapy, and multi-drug regimens, drawing lessons from genetically engineered mouse models, patient-derived xenografts, and biomarker-guided clinical trials. Recent advances demonstrate that previously undruggable targets, including KRAS, can now be modulated using mutation-specific inhibitors and combination therapies, achieving complete tumor regression in preclinical models. PARP inhibitors in BRCA-mutated PDAC exemplify the translation of precision medicine into patient benefit. Adaptive, biomarker-driven trials enhance the detection of therapeutic signals, while stromal reprogramming improves drug delivery and immune accessibility. Artificial intelligence and systems biology further support predictive modeling and optimization of trial design. Overall, translational research in PDAC shows that persistent mechanistic exploration, combination strategies, and innovative trial designs can overcome historical therapeutic barriers. Despite systemic challenges such as funding, regulatory hurdles, and structural limitations, these approaches provide a roadmap for improving clinical outcomes. Continued interdisciplinary collaboration and precision-guided interventions will be essential to fully realize the potential of these discoveries.
- 3 January 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (1) , 203-218
Adolescent Suicide in the United States: Trends, Determinants and Implications for Prevention
Adolescent suicide remains a major public health concern in the United States and has shown troubling increases over the past two decades. It is the second leading cause of death among adolescents, representing a critical challenge for national mental health and prevention systems. This rising mortality burden underscores persistent gaps in early identification, access to mental health services, and the implementation of effective prevention strategies for young people. This narrative review examines trends and determinants of adolescent suicide in the United States between 2000 and 2026, a period that captures major shifts in digital technology, mental health awareness, and societal disruptions affecting youth well-being. A structured literature search was conducted across major academic databases to identify peer-reviewed studies, surveillance reports, and policy documents on adolescent suicide epidemiology, risk factors, and prevention strategies. Evidence suggests a steady rise in the rate of suicide among adolescents since the early 2000s, with marked disparities across age, sex, race and ethnicity, and geographic regions thus raising significant equity concerns. Key contributing factors include mental health disorders, substance use, family and peer conflict, bullying, social media exposure, and access to lethal means. In contrast, protective factors such as supportive family relationships, school connectedness, community engagement, and cultural influences play a critical role in resilience and suicide prevention. Broader structural influences such as economic recession as well as large-scale public health crisis like the COVID-19 pandemic, have also significantly shaped adolescent mental health outcomes. The existing strategies include federal policy initiatives, mental health programs in schools, crisis intervention programs, and online-based initiatives. However, there have been challenges in the implementation of the strategies, lack of accessibility, and disparities. This review aims to emphasize the novelty of the integration of the evidence from the year 2000 to 2026. In order to strengthen the existing frameworks of mental health, it is important to develop a multisectoral approach that addresses individual as well as structural determinants of mental health. Moreover, the study aims to emphasize the ways through which mental health care can be improved.
- 3 January 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (1) , 203-218
Adolescent Suicide in the United States: Trends, Determinants and Implications for Prevention
Adolescent suicide remains a major public health concern in the United States and has shown troubling increases over the past two decades. It is the second leading cause of death among adolescents, representing a critical challenge for national mental health and prevention systems. This rising mortality burden underscores persistent gaps in early identification, access to mental health services, and the implementation of effective prevention strategies for young people. This narrative review examines trends and determinants of adolescent suicide in the United States between 2000 and 2026, a period that captures major shifts in digital technology, mental health awareness, and societal disruptions affecting youth well-being. A structured literature search was conducted across major academic databases to identify peer-reviewed studies, surveillance reports, and policy documents on adolescent suicide epidemiology, risk factors, and prevention strategies. Evidence suggests a steady rise in the rate of suicide among adolescents since the early 2000s, with marked disparities across age, sex, race and ethnicity, and geographic regions thus raising significant equity concerns. Key contributing factors include mental health disorders, substance use, family and peer conflict, bullying, social media exposure, and access to lethal means. In contrast, protective factors such as supportive family relationships, school connectedness, community engagement, and cultural influences play a critical role in resilience and suicide prevention. Broader structural influences such as economic recession as well as large-scale public health crisis like the COVID-19 pandemic, have also significantly shaped adolescent mental health outcomes. The existing strategies include federal policy initiatives, mental health programs in schools, crisis intervention programs, and online-based initiatives. However, there have been challenges in the implementation of the strategies, lack of accessibility, and disparities. This review aims to emphasize the novelty of the integration of the evidence from the year 2000 to 2026. In order to strengthen the existing frameworks of mental health, it is important to develop a multisectoral approach that addresses individual as well as structural determinants of mental health. Moreover, the study aims to emphasize the ways through which mental health care can be improved.
- 3 January 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (1) , 129-141
Inflammatory Biomarkers as Predictors of Stroke Severity and Outcome: A Narrative Review
Background: Each year, nearly 12 million people suffer a stroke worldwide, resulting in over 7 million deaths, and approximately one in four adults is predicted to experience a stroke in their lifetime. Despite advances in acute stroke care and rehabilitation, stroke remains a leading cause of long-term disability. Inflammation plays a key role in stroke pathophysiology, influencing severity and recovery, and specific inflammatory biomarkers are increasingly recognized as potential indicators of patient outcomes. Objective: This narrative review examines the role of inflammatory biomarkers in relation to stroke severity and long-term outcomes. Methods: We conducted a narrative review of published studies on inflammatory biomarkers in stroke. Relevant articles were identified through searches of PubMed, Google Scholar, Dimensions, and Web of Science from January 2000 to December 2025. Studies were included based on relevance to stroke severity, prognosis, and biomarker assessment, encompassing both observational and experimental research. The narrative approach was used to qualitatively summarize findings, highlight methodological gaps, and propose directions for future research. Results: Elevated inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), CLEC4G, CKAP4, LY75, and ITGA11, have been associated with greater stroke severity, higher risk of complications, and poorer functional recovery. Composite indices and longitudinal biomarker profiling provide additional insight into the dynamics of post-stroke inflammation, supporting early risk stratification. Key gaps remain, including lack of standardization in biomarker measurement and potential confounding factors, which limit clinical translation. Conclusion: Inflammatory biomarkers show promise as indicators of stroke severity and prognosis. While they may help guide risk assessment and inform future targeted interventions, further validation is needed before routine clinical implementation.
- 3 January 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (1) , 129-141
Inflammatory Biomarkers as Predictors of Stroke Severity and Outcome: A Narrative Review
Background: Each year, nearly 12 million people suffer a stroke worldwide, resulting in over 7 million deaths, and approximately one in four adults is predicted to experience a stroke in their lifetime. Despite advances in acute stroke care and rehabilitation, stroke remains a leading cause of long-term disability. Inflammation plays a key role in stroke pathophysiology, influencing severity and recovery, and specific inflammatory biomarkers are increasingly recognized as potential indicators of patient outcomes. Objective: This narrative review examines the role of inflammatory biomarkers in relation to stroke severity and long-term outcomes. Methods: We conducted a narrative review of published studies on inflammatory biomarkers in stroke. Relevant articles were identified through searches of PubMed, Google Scholar, Dimensions, and Web of Science from January 2000 to December 2025. Studies were included based on relevance to stroke severity, prognosis, and biomarker assessment, encompassing both observational and experimental research. The narrative approach was used to qualitatively summarize findings, highlight methodological gaps, and propose directions for future research. Results: Elevated inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), CLEC4G, CKAP4, LY75, and ITGA11, have been associated with greater stroke severity, higher risk of complications, and poorer functional recovery. Composite indices and longitudinal biomarker profiling provide additional insight into the dynamics of post-stroke inflammation, supporting early risk stratification. Key gaps remain, including lack of standardization in biomarker measurement and potential confounding factors, which limit clinical translation. Conclusion: Inflammatory biomarkers show promise as indicators of stroke severity and prognosis. While they may help guide risk assessment and inform future targeted interventions, further validation is needed before routine clinical implementation.